Skip to main content

Table 3 Anti-MCV IgA titer courses of responders and non-responders to RTX in relation to their achieved DAS28 response after six months of RTX treatment (according to the EULAR response criteria)

From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

Responders to RTX (RRs)
DAS28 response of 37 RRs at week 24 (number of RRs) mean AMCV IgA titer at baseline (U/ml) mean AMCV IgA titer at week 24 (U/ml) percentage change (absolute titer change)
DAS28 ≤2.6 remission (12/37) 141.94 30.00 78.86 % (111.93)
DAS28 ≤3.2 and >2.6 low disease activity (5/37) 33.85 17.06 49.61 % (16.79)
DAS28 ≤5.1 and >3.2 moderate disease activity (17/37) 83.52 37.26 55.39 % (46.26)
DAS28 >5.1 high disease activity (3/37) 14.32 8.45 41.00 % (8.87)
Non-responders to RTX (NRRs)
DAS28 response of 13 NRRs at week 24 (number of NRRs) mean AMCV IgA titer at baseline (U/ml) mean AMCV IgA titer at week 24 (U/ml) percentage change (absolute titer change)
DAS28 ≤2.6 remission (0/13) / / /
DAS28 ≤3.2 and>2.6 low disease activity (1/13) 46.11 55.56 17.01 % (9.45)
DAS28 ≤5.1 and >3.2 moderate disease activity (7/13) 290.79 270.51 06.97 % (20.27)
DAS28 >5.1 high disease activity (5/13) 71.41 221.49 67.76 % (150.08)
  1. AMCV, antibodies against mutated citrullinated vimentin; DAS28, 28-joint Disease Activity Score; EULAR, European League against Rheumatism; NRRs, non-responders to RTX; RRs, responders to RTX; RTX, rituximab